$11.08+0.10 (+0.91%)
Biodesix, Inc.
Biodesix, Inc. in the Healthcare sector is trading at $11.08. The stock is currently 45% below its 52-week high of $20.21, remaining 14.8% above its 200-day moving average. Technical signals show neutral RSI of 37 and bearish MACD signal, explaining why BDSX maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identi...
By Karen Roman SkylineDx said it can predict metastases and outperform existing staging systems for the country’s second most common type of skin cancer, Cutaneous Squamous Cell Carcinoma (CSCC). The results will be presented at the 22nd European Association of Dermato-Oncology Congress, held on April 23-25, 2026, in Prague and online. “This marks our first […]
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
LifeMD (LFMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Biodesix enters this update cycle with its fair value price target holding steady at US$30.00, as the latest estimate matches the prior US$30.00 figure. That stability sits against a backdrop of mixed analyst commentary, with bullish voices pointing to an Outperform rating, stronger than expected 2026 guidance, and an improved balance sheet, while more cautious views question how durable recent execution and visibility really are. As you read on, you will see how these competing arguments...
DexCom's expanding CGM market, G7 rollout, and global growth momentum position it for gains, despite pricing pressure and near-term margin risks.